Asset Details
Do you wish to reserve the book?
A clinical utility study of exome sequencing versus conventional genetic testing in pediatric neurology
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A clinical utility study of exome sequencing versus conventional genetic testing in pediatric neurology
Do you wish to request the book?
A clinical utility study of exome sequencing versus conventional genetic testing in pediatric neurology
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A clinical utility study of exome sequencing versus conventional genetic testing in pediatric neurology
2017
Overview
Purpose:
Implementation of novel genetic diagnostic tests is generally driven by technological advances because they promise shorter turnaround times and/or higher diagnostic yields. Other aspects, including impact on clinical management or cost-effectiveness, are often not assessed in detail prior to implementation.
Methods:
We studied the clinical utility of whole-exome sequencing (WES) in complex pediatric neurology in terms of diagnostic yield and costs. We analyzed 150 patients (and their parents) presenting with complex neurological disorders of suspected genetic origin. In a parallel study, all patients received both the standard diagnostic workup (e.g., cerebral imaging, muscle biopsies or lumbar punctures, and sequential gene-by-gene–based testing) and WES simultaneously.
Results:
Our unique study design allowed direct comparison of diagnostic yield of both trajectories and provided insight into the economic implications of implementing WES in this diagnostic trajectory. We showed that WES identified significantly more conclusive diagnoses (29.3%) than the standard care pathway (7.3%) without incurring higher costs. Exploratory analysis of WES as a first-tier diagnostic test indicates that WES may even be cost-saving, depending on the extent of other tests being omitted.
Conclusion:
Our data support such a use of WES in pediatric neurology for disorders of presumed genetic origin.
Genet Med
advance online publication 23 March 2017
Publisher
Nature Publishing Group US,Elsevier Limited,Nature Publishing Group
Subject
/ Biomedical and Life Sciences
/ Child
/ Female
/ Genetic Testing - statistics & numerical data
/ Humans
/ Infant
/ Male
/ Neurology - statistics & numerical data
/ Original
/ Patient Acceptance of Health Care - statistics & numerical data
/ Pediatrics - statistics & numerical data
/ Standard of Care - economics
/ Standard of Care - standards
/ Standard of Care - statistics & numerical data
